Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
Upturn AI SWOT - About
Tema Oncology ETF (CANC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: CANC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type ETF | Historic Profit 16.9% | Avg. Invested days 49 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | ETF Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Volume (30-day avg) - | Beta - | 52 Weeks Range 20.10 - 29.30 | Updated Date 06/30/2025 |
52 Weeks Range 20.10 - 29.30 | Updated Date 06/30/2025 |
Upturn AI SWOT
Tema Oncology ETF
ETF Overview
Overview
The Tema Oncology ETF (CNCR) is a thematic ETF focused on companies involved in cancer treatment, diagnostics, and research. It aims to capitalize on the growing market for oncology-related products and services through investments in biotech, pharmaceuticals, and medical technology companies. The fund provides targeted exposure to the oncology sector.
Reputation and Reliability
Tema ETFs are relatively new to the market. As such, they lack a long track record, and their reputation is still developing.
Management Expertise
The management team possesses expertise in thematic investing and identifies companies poised to benefit from the rise of cancer-related industries.
Investment Objective
Goal
The investment goal of the Tema Oncology ETF is to provide investors with exposure to companies involved in the oncology sector, aiming for long-term capital appreciation.
Investment Approach and Strategy
Strategy: The ETF does not track a specific index. It employs a thematic investment approach, selecting companies involved in cancer treatment, diagnostics, and research.
Composition The ETF primarily holds stocks of companies in the biotechnology, pharmaceuticals, and healthcare equipment and services sectors. The specific holdings are actively managed.
Market Position
Market Share: Data on exact market share is not publicly available. This ETF is new and focuses on a narrow thematic strategy within the broader healthcare and biotechnology industries.
Total Net Assets (AUM): 3390000
Competitors
Key Competitors
- IBB
- XBI
- PJP
- XLV
Competitive Landscape
The ETF market for healthcare and biotechnology is competitive. CNCR is a new ETF with a very small market share that sets it apart from established broad-based ETFs like IBB and XBI. CNCR offers a more focused oncology theme, potentially outperforming broad healthcare ETFs if the oncology sector performs well. However, its small size may translate to higher trading costs and volatility.
Financial Performance
Historical Performance: Historical performance data is limited due to the ETF's recent inception. Investors should consider performance data from inception to present.
Benchmark Comparison: A relevant benchmark comparison would be the performance of the Nasdaq Biotechnology Index (NBI).
Expense Ratio: 0.75
Liquidity
Average Trading Volume
The average trading volume is relatively low which indicates potentially wider bid-ask spreads.
Bid-Ask Spread
The bid-ask spread varies depending on market conditions and trading volume, but is typically wider than more liquid ETFs due to lower trading volume.
Market Dynamics
Market Environment Factors
The ETF's performance is influenced by factors such as advancements in cancer research, regulatory approvals of new cancer therapies, demographic trends (aging population), and healthcare spending policies.
Growth Trajectory
The growth trajectory depends on the continued innovation in cancer treatment, diagnostics, and prevention, as well as the overall health of the biotechnology and pharmaceutical industries.
Moat and Competitive Advantages
Competitive Edge
The Tema Oncology ETF's advantage lies in its targeted exposure to the oncology sector, which offers potential for higher growth than broader healthcare ETFs. Its thematic approach allows investors to focus on a specific area of medical innovation. However, the focused approach can make it more volatile. It may appeal to investors who have high conviction in the continued development of Oncology.
Risk Analysis
Volatility
The ETF's volatility is expected to be higher than broader market ETFs due to its focused investment strategy.
Market Risk
The ETF is subject to market risk, particularly risks specific to the biotechnology and pharmaceutical industries, such as clinical trial failures, regulatory setbacks, and patent expirations. It is also subject to sector specific risks.
Investor Profile
Ideal Investor Profile
The ideal investor is someone with a high risk tolerance who is bullish on the long-term prospects of the oncology sector.
Market Risk
The ETF is best suited for long-term investors who understand the risks and potential rewards of investing in a specific sector.
Summary
Tema Oncology ETF provides targeted exposure to companies involved in cancer treatment, diagnostics, and research. It's a thematic ETF that aims for long-term capital appreciation within the oncology sector. Due to its specific focus, it carries a higher risk and may have higher volatility. This ETF is suitable for investors with a higher risk tolerance who are looking for a focused investment in oncology.
Peer Comparison
Sources and Disclaimers
Data Sources:
- etf.com
- sec.gov
- Issuer website
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on your own due diligence and assessment of risk tolerance. Data may be delayed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tema Oncology ETF
Exchange NASDAQ | Headquaters - | ||
IPO Launch date - | CEO - | ||
Sector - | Industry - | Full time employees - | Website |
Full time employees - | Website | ||
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.